Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2025 value amounting to $22.3 million.

  • RedHill Biopharma's Total Current Liabilities rose 496.4% to $22.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $22.3 million, marking a year-over-year increase of 496.4%. This contributed to the annual value of $22.2 million for FY2024, which is 1120.95% up from last year.
  • Latest data reveals that RedHill Biopharma reported Total Current Liabilities of $22.3 million as of Q2 2025, which was up 496.4% from $22.2 million recorded in Q4 2024.
  • In the past 5 years, RedHill Biopharma's Total Current Liabilities registered a high of $197.5 million during Q4 2022, and its lowest value of $20.0 million during Q4 2023.
  • For the 5-year period, RedHill Biopharma's Total Current Liabilities averaged around $70.9 million, with its median value being $28.2 million (2023).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 14236.41% in 2022, then tumbled by 8987.97% in 2023.
  • RedHill Biopharma's Total Current Liabilities (Quarter) stood at $81.5 million in 2021, then surged by 142.36% to $197.5 million in 2022, then crashed by 89.88% to $20.0 million in 2023, then grew by 11.21% to $22.2 million in 2024, then rose by 0.29% to $22.3 million in 2025.
  • Its Total Current Liabilities stands at $22.3 million for Q2 2025, versus $22.2 million for Q4 2024 and $21.2 million for Q2 2024.